Stiris Research Inc. completes Phase II Meniere’s disease study

London, ON — September 26, 2017 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces that it has completed and closed a US biotechnology company’s Phase II Meniere’s disease study.

“Our Canadian sites all achieved great success on this study and allowed the sponsor to close the study earlier than anticipated. We always appreciate working with engaged sites who pride themselves on good, clean, quality data and patient safety. It makes what we do at Stiris that much easier when we have collaborative sites to work with,” said Amanda Carrera, Vice President.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.